Ketan Desai - Comments
CEO of International Medical Consultants, IMC Radiology, and CMO of Levolta Pharma
Ketan Desai, MD, PhD, is the Founder and Chief Executive Officer of IMC Radiology, the founder and Chief Medical Officer of LeVolta Pharma (biotechnology), Founder and Chairperson of Omega Skin Solutions ...more
Latest Comments
Review Of Present Therapies For Covid-19
2 years ago

CYDY is still a garbage company.  Nothing has changed there.  Dont know why the chart is no longer showing.  Must be some software problem at TM

In this article: LLY, MRK, CYDY, REGN, HGEN, RLFTF
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
3 years ago

What is sad is your ignorant pumping.  Nothing was done to this stock, it went down as there was no science, no management, no clinical or regulatory path forward.  And no, it does not go to show any stock has "unknown things and is unpredictable" - I've been bearish on this for over a year while you were shamelessly pumping.  

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
3 years ago

Still pumping this garbage?  Has failed every study, been scoled by the FDA for lying, has had 25 different firms file lawsuits, lost a distributor in US, and stock is now down to $1.40 or thereabouts. When you started pumping this stock, it was in the $4 range.  Have you no shame?

In this article: CYDY
Review Of Present Therapies For Covid-19
3 years ago

Thanks. Your point of placebo is well taken. Often though, it is not true placebo. The design is standard of care plus study drug versus standard of care plus placebo. The patients thus get the minimum of standard of care.

In this article: LLY, MRK, CYDY, REGN, HGEN, RLFTF
Review Of Present Therapies For Covid-19
3 years ago

Thanks

In this article: LLY, MRK, CYDY, REGN, HGEN, RLFTF
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
4 years ago

Written by Cytodyn insiders!! What conflict of interest!! Zero credibilty!! LOL!!!!

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
4 years ago

What an ignorant and biased rant. Look at these reviews on the status of immune response to COVID19. These are by independent scientists who, unlike you or Cytodyn, have no conflict of interest. They are peer reviewed and are in world class journals Sciene, Lancet. CCR5 is not a pathway that anyone of repute espouses.

www.sciencedirect.com/.../S1074761320301837

science.sciencemag.org/content/369/6508/eabc8511

www.thelancet.com/.../fulltext#seccestitle60

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
4 years ago

What a poor response. You DID NOT SHOW A SINGLE PEER REVIEWED INDEPENDENT ARTICLE ON CCR5 AND COVID19. We are not talking about HIV but COVID19. Stay on topic, will you, and stop dissembling the truth?

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
4 years ago

Scientific knowledge that Cytodyn pumpers dont know or deliberately obfuscate - neutrophils in COVID19 are determined by CCR8, and not CCR5. See article below. Leronlimab binds CCR5, not CCR8. Which is why other than Cytodyn, NOBODY IN THE SCIENTIFIC OR PHARMA COMMUNITY trusts cytodyn data.

In this article: CYDY
1 to 10 of 24 comments